Clinical Trial Update: Allogeneic CART-33 for Relapsed/Refractory CD33+ AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic CART-33 therapy for relapsed/refractory CD33-positive acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allogeneic CART-33 (CAR-T therapy targeting CD33 (allogeneic))

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Relapsed and/or Refractory CD33+ AML | Phase 1 | Status: UNKNOWN